Pubblicazioni e Impact factor
| Anno | N° pubblicazioni | IF normalizzato | IF per ricercatore | IF per ricercatore con pubblicazioni |
|---|---|---|---|---|
| 2022 | 302 | 1.761,87 | 4,98 | 8,69 |
| 2021 | 393 | 1.822,73 | 5,74 | 8,96 |
| 2020 | 352 | 1.764,86 | 5,77 | 10,59 |
Pubblicazioni
| Titolo | Autori | Rivista | IF grezzo |
|---|---|---|---|
| Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial | Andrea Sartore-Bianchi, Filippo Pietrantonio, Lonardi Sara, Benedetta Mussolin, Francesco Rua, Giovanni Crisafulli, Alice Bartolini, Elisabetta Fenocchio, Alessio Amatu, Paolo Manca, bergamo francesca, Federica Tosi, Gianluca Mauri, Margherita Ambrosini, Daniel Francesca, Valter Torri, Angelo Vanzulli, Daniele Regge, Giovanni Cappello, Caterina Marchiò, Enrico Berrino, Anna Sapino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli | NATURE MEDICINE | 87,24 |
| RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer | Elena Elez, Javier Ros, Jose Fernández, Guillermo Villacampa, Ana Belén Moreno-Cárdenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Intini Rossana, Montagna Aldo, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Lonardi Sara, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo | NATURE MEDICINE | 87,24 |
| Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial | Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, Aurélie Catteau, Lisa Salvatore, Lonardi Sara, Isabelle Boquet, Stefano Tamberi, Federica Marmorino, Roberto Moretto, Margherita Ambrosini, Emiliano Tamburini, Giampaolo Tortora, Alessandro Passardi, bergamo francesca, Alboukadel Kassambara, Thomas Sbarrato, Federica Morano, Giuliana Ritorto, Beatrice Borelli, Alessandra Boccaccino, Veronica Conca, Mirella Giordano, Clara Ugolini, Jacques Fieschi, Alexia Papadopulos, Clémentine Massoué, Giuseppe Aprile, Lorenzo Antonuzzo, Fabio Gelsomino, Erika Martinelli, Nicoletta Pella, Gianluca Masi, Gabriella Fontanini, Luca Boni, Jérôme Galon, Chiara Cremolini | LANCET ONCOLOGY | 54,43 |
| Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice? | Rodrigo Dienstmann, Lonardi Sara | LANCET ONCOLOGY | 54,43 |
| Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial | Paolo A. Ascierto, Mario Mandalà, Pier Francesso Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, chiarion sileni vanna | JOURNAL OF CLINICAL ONCOLOGY | 50,74 |
| Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO | Daniele Rossini, Carlotta Antoniotti, Lonardi Sara, Filippo Pietrantonio, Roberto Moretto, Lorenzo Antonuzzo, Alessandra Boccaccino, Federica Morano, Marco Brugia, Carmelo Pozzo, Federica Marmorino, bergamo francesca, Emiliano Tamburini, Alessandro Passardi, Giovanni Randon, Murgioni Sabina, Beatrice Borelli, Angela Buonadonna, Mirella Giordano, Gabriella Fontanini, Veronica Conca, Vincenzo Formica, Massimo Aglietta, Roberto Bordonaro, Giuseppe Aprile, Gianluca Masi, Luca Boni, Chiara Cremolini | JOURNAL OF CLINICAL ONCOLOGY | 50,74 |
| Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial | Federica Morano, Alessandra Raimondi, Filippo Pagani, Lonardi Sara, Lisa Salvatore, Chiara Cremolini, Murgioni Sabina, Giovanni Randon, Federica Palermo, Lorenzo Antonuzzo, Nicoletta Pella, Patrizia Racca, Michele Prisciandaro, Monica Niger, Francesca Corti, bergamo francesca, Alberto Zaniboni, Margherita Ratti, Michele Palazzo, Celeste Cagnazzo, Maria Alessandra Calegari, Federica Marmorino, Iolanda Capone, Elena Conca, Adele Busico, Silvia Brich, Elena Tamborini, Federica Perrone, Massimo Di Maio, Massimo Milione, Maria Di Bartolomeo, Filippo De Braud, Filippo Pietrantonio | JOURNAL OF CLINICAL ONCOLOGY | 50,74 |
| Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials | Claire Gallois, Qian Shi, Jeffrey Meyers, Lonardi Sara, Greg Yothers, Julien Taieb | JOURNAL OF CLINICAL ONCOLOGY | 50,74 |
| Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) | Roberta Sanfilippo, Richard L. Hayward, Jammbe Musoro, Charlotte Benson, Michael Gordon Leahy, Brunello Antonella, Jean-Yves Blay, Neeltje Steeghs, Ingrid M. E. Desar, Nasim Ali, Alice Hervieu, Khin Thway, Sandrine Marreaud, Saskia Litiere, Bernd Kasper | JAMA Oncology | 33,01 |
| Autoimmune gastritis: Long-Term natural history in naïve Helicobacter pylori-negative patients | Massimo Rugge, Ludovica Bricca, Stefano Guzzinati, Diana Sacchi, Marco Pizzi, Edoardo Savarino, Fabio Farinati, Manuel Zorzi, Fassan Matteo, Angelo Paolo Dei Tos, Peter Malfertheiner, Robert M Genta, David Y Graham | GUT | 31,80 |
| A Novel Benchmarking Approach to Assess the Agreement among Radiomic Tools | Bettinelli Andrea, Marturano Francesca, Michele Avanzo, Emiliano Loi, Enrico Menghi, Emilio Mezzenga, Giovanni Pirrone, Anna Sarnelli, Lidia Strigari, Silvia Strolin, paiusco marta | RADIOLOGY | 29,15 |
| Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance | Patrizia Romani, Nunzia Nirchio, Mattia Arboit, Barbieri Vito, Tosi Anna, Federica Michielin, Soichi Shibuya, Thomas Benoist, Danchen Wu, Charles Colin Thomas Hindmarch, Monica Giomo, Anna Urciuolo, Flavia Giamogante, Antonella Roveri, Marco Montagner, Probir Chakravarty, Tito Calì, Nicola Elvassore, Stephen L. Archer, Paolo De Coppi, Rosato Antonio, Graziano Martello, Sirio Dupont | NATURE CELL BIOLOGY | 28,21 |
| Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair | Silvia Alvarez, Ana C. da Silva Almeida, Robert Albero, Mayukh Biswas, Angelica Barreto-Galvez, Thomas S. Gunning, Anam Shaikh, Tomas Aparicio, Agnieszka Wendorff, Piovan Erich, Pieter Van Vlierberghe, Steven Gygi, Jean Gautier, Advaitha Madireddy, Adolfo A. Ferrando | BLOOD | 25,67 |
| Tyd LGL leukemia identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients | G Barilà, Grassi Angela, H Cheon, G Semenzato, R Zambello | BLOOD | 25,67 |
| Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse | Chiara Rusconi, Chan Y. Cheah, Toby A. Eyre, David Tucker, Pavel Klener, Eva Giné, Lara Crucitti, Cristina Muzi, Sara Iadecola, Gabriele Infante, Sophie Bernard, Rebecca L. Auer, Chiara Pagani, Monika Duglosz-Danecka, Heidi Mocikova, Tom van Meerten, Emanuele Cencini, Ana Marin-Niebla, Michael E. Williams, Piera Angelillo, Paolo Nicoli, Annalisa Arcari, Lucia Morello, Donato Mannina, Orsola Vitagliano, Sartori Roberto, Annalisa Chiappella, Roberta Sciarra, Piero M. Stefani, Martin Dreyling, John F. Seymour, Carlo Visco | BLOOD | 25,67 |
| Titolo | Autori | Rivista | IF grezzo |
|---|---|---|---|
| Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma | CheckMate 9ER Investigators Gruppo, Choueiri T. K., Powles T., Burotto M., Escudier B., Bourlon M. T., Zurawski B., Juárez V. M.Oyervides, Hsieh J. J., BASSO UMBERTO, Shah A. Y., Suárez C., Hamzaj A., Goh J. C., Barrios C., Richardet M., Porta C., Kowalyszyn R., Feregrino J. P., Zolnierek J., Pook D., Kessler E. R., Tomita Y., Mizuno R., Bedke J., Zhang J., Maurer M. A., Simsek B., Ejzykowicz F., Schwab G. M., Apolo A. B., Motzer R. J. | NEW ENGLAND JOURNAL OF MEDICINE | 91.253 |
| Immune checkpoint inhibitors in mesothelioma: a turning point | Ceresoli Giovanni Luca, Pasello Giulia | LANCET | 79.323 |
| The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer | Janjigian Yelena Y, Kawazoe Akihito, Yañez Patricio, Li Ning, Lonardi Sara, Kolesnik Oleksii, Barajas Olga, Bai Yuxian, Shen Lin, Tang Yong, Wyrwicz Lucjan S, Xu Jianming, Shitara Kohei, Qin Shukui, Van Cutsem Eric, Tabernero Josep, Li Lie, Shah Sukrut, Bhagia Pooja, Chung Hyun Cheol | NATURE | 49.962 |
| Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer | Iveson Timothy J., Sobrero Alberto F., Yoshino Takayuki, Souglakos Ioannis, Ou Fang Shu, Meyers Jeffrey P., Shi Qian, Grothey Axel, Saunders Mark P., Labianca Roberto, Yamanaka Takeharu, Boukovinas Ioannis, Hollander Niels H., Galli Fabio, Yamazaki Kentaro, Georgoulias Vassilis, Kerr Rachel, Oki Eiji, Lonardi Sara, Harkin Andrea, Rosati Gerardo, Paul James | JOURNAL OF CLINICAL ONCOLOGY | 44.544 |
| Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin | Fontana Elisa, Meyers Jeff, Sobrero Alberto, Iveson Timothy, Shields Anthony F., Taieb Julien, Yoshino Takayuki, Souglakos Ioannis, Smyth Elizabeth C., Lordick Florian, Moehler Markus, Giraut Anne, Harkin Andrea, Labianca Roberto, Meyerhardt Jeffrey, André Thierry, Boukovinas Ioannis, Lonardi Sara, Saunders Mark, Vernerey Dewi, Oki Eiji, Georgoulias Vassilis, Ben-Aharon Irit, Shi Qian | JOURNAL OF CLINICAL ONCOLOGY | 44.544 |
| Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study | Tabernero Josep, Grothey Axel, van Cutsem Eric, Yaeger Rona, Wasan Harpreet, Yoshino Takayuki, Desai Jayesh, Ciardiello Fortunato, Loupakis Fotios, Hong Yong Sang, Steeghs Neeltje, Guren Tormod Kyrre, Arkenau Hendrik Tobias, Garcia-Alfonso Pilar, Elez Elena, Gollerkeri Ashwin, Maharry Kati, Christy-Bittel Janna, Kopetz Scott | JOURNAL OF CLINICAL ONCOLOGY | 44.544 |
| First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study | Lenz Heinz-Josef, Van Cutsem Eric, Luisa Limon Maria, Wong Ka Yeung Mark, Hendlisz Alain, Aglietta Massimo, García-Alfonso Pilar, Neyns Bart, Luppi Gabriele, Cardin Dana B, Dragovich Tomislav, Shah Usman, Abdullaev Sandzhar, Gricar Joseph, Ledeine Jean-Marie, Overman Michael James, Lonardi Sara | JOURNAL OF CLINICAL ONCOLOGY | 44.544 |
| Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2- Negative Advanced Breast Cancer from SOLAR-1 | Ciruelos Eva Maria, Rugo Hope S., Mayer Ingrid A., Levy Christelle, Forget Frederic, Mingorance Juan Ignacio Delgado, Safra Tamar, Masuda Norikazu, Park Yeon Hee, Juric Dejan, Conte Pierfranco, Campone Mario, Loibl Sibylle, Iwata Hiroji, Zhou Xiaolei, Park Jinhee, Ridolfi Antonia, Lorenzo Ines, André Fabrice | JOURNAL OF CLINICAL ONCOLOGY | 44.544 |
| Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA) | Hecht J. Randolph, Lonardi Sara, Bendell Johanna, Sim Hao Wen, Macarulla Teresa, Lopez Charles D., Van Cutsem Eric, Muñoz Martin Andres J., Park Joon Oh, Greil Richard, Wang Hong, Hozak Rebecca R., Gueorguieva Ivelina, Lin Yong, Rao Sujata, Ryoo Baek Yeol | JOURNAL OF CLINICAL ONCOLOGY | 44.544 |
| Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi | Merli Francesco, Luminari Stefano, Tucci Alessandra, Arcari Annalisa, Rigacci Luigi, Hawkes Eliza, Chiattone Carlos S, Cavallo Federica, Cabras Giuseppina, Alvarez Isabel, Fabbri Alberto, Re Alessandro, Puccini Benedetta, Barraclough Allison, Delamain Marcia Torresan, Ferrero Simone, Usai Sara Veronica, Ferrari Angela, Cencini Emanuele, Pennese Elsa, Zilioli Vittorio Ruggero, Marino Dario, Balzarotti Monica, Cox Maria Christina, Zanni Manuela, Di Rocco Alice, Lleshi Arben, Botto Barbara, Hohaus Stefan, Merli Michele, Sartori Roberto, Gini Guido, Nassi Luca, Musuraca Gerardo, Tani Monica, Bottelli Chiara, Kovalchuk Sofia, Re Francesca, Flenghi Leonardo, Molinari Annalia, Tarantini Giuseppe, Chimienti Emanuela, Marcheselli Luigi, Mammi Caterina, Spina Michele | JOURNAL OF CLINICAL ONCOLOGY | 44.544 |
| Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis | Passiglia Francesco, Cinquini Michela, Bertolaccini Luca, Del Re Marzia, Facchinetti Francesco, Ferrara Roberto, Franchina Tindara, Larici Anna R, Malapelle Umberto, Menis Jessica, Passaro Antonio, Pilotto Sara, Ramella Sara, Rossi Giulio, Trisolini Rocco, Novello Silvia | JOURNAL OF CLINICAL ONCOLOGY | 44.544 |
| Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial | Investigators MITO16b/MANGO¿OV2/ENGOT¿ov17, Pignata Sandro, Lorusso Domenica, Joly F., Gallo Ciro, Colombo N., Sessa Cristiana, Bamias Aristotelis, Salutari Vanda, Selle Frédèric, FREZZINI SIMONA, De Giorgi U., Pautier P., Bologna Alessandra, Orditura Michele, Dubot C., Gadducci Angiolo, Mammoliti S., Ray-Coquard I., Zafarana E., Breda Enrico, Favier L., Ardizzoia Antonio, Cinieri Saverio, Largillier R., Sambataro Daniela, Guardiola Emmanuel, Lauria R., Pisano C., Raspagliesi F., Scambia Giovanni, Daniele Gennaro, Perrone Francesco | LANCET ONCOLOGY | 41.316 |
| Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis | Groups MACH-NC and MARCH Collaborative, Petit Claire, Lacas Benjamin, Pignon Jean Pierre, Le Quynh Thu, Grégoire Vincent, Grau Cai, Hackshaw Allan, Zackrisson Björn, Parmar Mahesh K.B., Lee Ju Whei, Ghi Maria Grazia, Sanguineti Giuseppe, Temam Stéphane, Cheugoua-Zanetsie Maurice, O’Sullivan Brian, Posner Marshall R., Vokes Everett E., Cruz Hernandez Juan J., Szutkowski Zbigniew, Lartigau Eric, Budach V., Suwi¿ski Rafal, Poulsen Michael, Kumar Shaleen, Ghosh Laskar Sarbani, Mazeron Jean Jacques, Jeremic Branislav, Simes John, Zhong Lai Ping, Overgaard Jens, Fortpied Catherine, Torres-Saavedra Pedro, Bourhis Jean, Aupérin A., Blanchard P., Adelstein D. J., Agarwal J., Alfonsi M., Argiris A., Aupérin A., Bacigalupo A., Bar-Ad V., Bartelink H., Beadle B., Fallai C., Licitra L., Orecchia R., Torri V. | LANCET ONCOLOGY | 41.316 |
| Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial | Pinto C., Zucali P.A., Pagano M., Grosso F., Pasello Giulia, Garassino M.C., Tiseo M., Soto Parra H., Grossi F., Cappuzzo F., de Marinis F., Pedrazzoli P., Bonomi M., Gianoncelli L., Perrino M., Santoro A., Zanelli F., Bonelli C., Maconi A., Frega Stefano, Gervasi E., Boni L., Ceresoli G.L. | LANCET ONCOLOGY | 41.316 |
| HER2: a never ending story | DIECI MARIA VITTORIA, Miglietta Federica | LANCET ONCOLOGY | 41.316 |
| Titolo | Autori | Rivista | IF grezzo |
|---|---|---|---|
| Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma | Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni Vanna, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D. | The New England Journal of Medicine | 74.699 |
| Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer | Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno Laura, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. | The New England Journal of Medicine | 74.699 |
| Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte Pierfranco, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. | The New England Journal of Medicine | 74.699 |
| Cancer and COVID-19: what do we really know? | Poortmans,P. M., Guarneri Valentina, Cardoso,M. -J | Lancet | 60.392 |
| Reprogramming normal cells into tumour precursors requires ECM stiffness and oncogene-mediated changes of cell mechanical properties | Panciera T, Citron A, Di Biagio D, Battilana G, Gandin A, Giulitti S, Forcato M, Bicciato S, Panzetta V, Fusco S, Azzolin L, Totaro A, Dei Tos AP, Fassan M, Vindigni V, Bassetto F, Rosato Antonio, Brusatin G, Cordenonsi M, Piccolo S. | Nature Materials | 38.663 |
| A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation | Prat,A., Guarneri Valentina, Parè,L., Griguolo Gaia, Pascual,T., Dieci Maria Vittoria, Chic,N., Gonzalez-Farrè,B., Frassoldati,A., Sanfeliu,E., Cejalvo,J. M., Munoz,M., Bisagni,G., Braso-Maristany,F., Urso,L., Vidal,M., Brandes,A. A., Adamo,B., Musolino,A., MIGLIETTA FEDERICA (…) | Lancet Oncology | 33.752 |
| A new standard of care for patients with high-risk rhabdomyosarcoma? – Authors’ reply | Bisogno,G., Ferrari,A., Melcon,S. G., De Salvo Gian Luca, Bergeron,C., Jenney,M. | Lancet Oncology | 33.752 |
| Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial | Dummer,R., Brase,J. C., Garrett,J., Campbell,C. D., Gasal,E., Squires,M., Gusenleitner,D., Santinami,M., Atkinson,V., Mandalà ,M., Chiarion-Sileni Vanna, Flaherty,K., Larkin,J., Robert,C., Kefford,R., Kirkwood,J. M., Hauschild,A., Schadendorf,D., Long,G. V. | Lancet Oncology | 33.752 |
| Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial | Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni Vanna, Márquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, Weber J. | Lancet Oncology | 33.752 |
| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study | Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello Giulia, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L; TERAVOLT investigators. | Lancet Oncology | 33.752 |
| Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial | Bonvalot S, Gronchi A, Le Péchoux C, Swallow CJ, Strauss D, Meeus P, van Coevorden F, Stoldt S, Stoeckle E, Rutkowski P, Rastrelli Marco, Raut CP, Hompes D, De Paoli A, Sangalli C, Honoré C, Chung P, Miah A, Blay JY, Fiore M, Stelmes JJ, Dei Tos AP, Baldini EH, Litière S, Marreaud S, Gelderblom H, Haas RL. | Lancet Oncology | 33.752 |
| Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study | Koller M, Shamieh O, Hjermstad MJ, Hornslien K, Young T, Chalk T, Ioannidis G, Harle A, Johnson CD, Tomaszewski KA, Serpentini Samantha, Pinto M, van der Weijst L, Janssens A, Morag O, Chie WC, Arraras JI, Pompili C, Jungraithmayr W, Hechtner M, Katsochi D, Müller K, Gräfenstein L, Schulz C, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; EORTC Lung Cancer Group; European Society of Thoracic Surgeons. | Lancet Oncology | 33.752 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial | Cremolini C, Antoniotti C, Rossini D, Lonardi Sara, Loupakis Fotios, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni Sabina, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel Vittorina, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. | Lancet Oncology | 33.752 |
I dati pubblicati in questa pagina sono forniti dalla Biblioteca scientifica IOV.